Department of Head and Neck Surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Department of Central Laboratory, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
J Cell Physiol. 2020 Oct;235(10):6942-6953. doi: 10.1002/jcp.29590. Epub 2020 Feb 6.
Tongue squamous cell carcinoma (TSCC) is more aggressive than other head and neck tumors, and the prognosis for patients with advanced TSCC is poor. At present, comprehensive treatment based on surgery as the main method is not effective for patients with advanced TSCC. The application of PD-1/PD-L1 immunocheckpoint inhibitor alone in patients with TSCC has not been reported. To explore the role of PD-1/PD-L1, we investigated the expression of PD-1 and PD-L1 in TSCC and analyzed the relationship between the expression of PD-1 and PD-L1 and the related clinicopathological parameters and survival prognosis. The expression of PD-1 was significantly associated with palindromia (p = .015) and maximum diameter (p = .043). The expression of PD-L1 in tumor cells was significantly associated with N stage (P = .024), chemotherapy (p = .032), and clinical stage (p = .019). The expression of PD-L1 in infiltrating lymphocytes was significantly associated with palindromia (p = .030). Univariate and multivariate Cox analyses for prognoses of patients showed significant prognostic factors of overall survival and relapse-free survival. The high expression of PD-L1 on infiltrating lymphocytes for OS and RFS was an independent protective factor for patients with TSCC. The high expression of PD-1 on infiltrating lymphocytes and clinical stage for OS and RFS were independent risk factors for patients with TSCC. The data provide a reference for clinical treatment of TSCC with immunotherapy.
舌鳞状细胞癌（TSCC）比其他头颈部肿瘤更具侵袭性，晚期 TSCC 患者的预后较差。目前，以手术为主的综合治疗对晚期 TSCC 患者效果不佳。PD-1/PD-L1 免疫检查点抑制剂单独应用于 TSCC 患者的报道尚未见报道。为了探讨 PD-1/PD-L1 的作用，我们研究了 PD-1 和 PD-L1 在 TSCC 中的表达，并分析了 PD-1 和 PD-L1 的表达与相关临床病理参数和生存预后的关系。PD-1 的表达与 palindromia（p = .015）和最大直径（p = .043）显著相关。肿瘤细胞中 PD-L1 的表达与 N 分期（P = .024）、化疗（p = .032）和临床分期（p = .019）显著相关。浸润淋巴细胞中 PD-L1 的表达与 palindromia 显著相关（p = .030）。单因素和多因素 Cox 分析显示，总生存和无复发生存的预后均有显著的预后因素。浸润淋巴细胞中 PD-L1 的高表达对 OS 和 RFS 是 TSCC 患者的独立保护因素。浸润淋巴细胞中 PD-1 的高表达和临床分期对 OS 和 RFS 是 TSCC 患者的独立危险因素。该数据为 TSCC 的免疫治疗提供了临床参考。
